Works matching IS 2160763X AND DT 2019 AND VI 8 AND IP 7
Results: 14
Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy‐Induced Nausea and Vomiting.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 850, doi. 10.1002/cpdd.733
- By:
- Publication type:
- Article
Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 884, doi. 10.1002/cpdd.722
- By:
- Publication type:
- Article
Correction.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 971, doi. 10.1002/cpdd.719
- Publication type:
- Article
A Randomized, Placebo‐Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High‐Density Lipoprotein Cholesterol in Subjects With Dyslipidemia.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 871, doi. 10.1002/cpdd.704
- By:
- Publication type:
- Article
Pharmacokinetic Interactions Between the Fixed‐Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 952, doi. 10.1002/cpdd.702
- By:
- Publication type:
- Article
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct‐Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse‐Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 962, doi. 10.1002/cpdd.701
- By:
- Publication type:
- Article
Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 861, doi. 10.1002/cpdd.698
- By:
- Publication type:
- Article
Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 895, doi. 10.1002/cpdd.692
- By:
- Publication type:
- Article
Study on Drug‐Drug Interactions Between Chiglitazar, a Novel PPAR Pan‐Agonist, and Metformin Hydrochloride in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 934, doi. 10.1002/cpdd.668
- By:
- Publication type:
- Article
Use of Population Pharmacokinetic Analyses Among FDA‐Approved Biologics.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 914, doi. 10.1002/cpdd.658
- By:
- Publication type:
- Article
Exposure‐Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Patients.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 903, doi. 10.1002/cpdd.646
- By:
- Publication type:
- Article
A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 922, doi. 10.1002/cpdd.642
- By:
- Publication type:
- Article
Safety and Tolerability of the Chymase Inhibitor Fulacimstat in Patients With Left Ventricular Dysfunction After Myocardial Infarction—Results of the CHIARA MIA 1 Trial.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 942, doi. 10.1002/cpdd.633
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 7, p. 845, doi. 10.1002/cpdd.595
- Publication type:
- Article